Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · cited 11×
“A detailed description of the study has been published elsewhere [14, 15].”
BackgroundResultInfluentialSelf-citationKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“The relation between cholesterol and risk of cardiovascular disease is complicated in the sense that observational studies have shown that, unlike in middle age, high total serum cholesterol levels are no longer associated with cardiovascular disease and cognitive impairment in old age [8, 17].”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.
Snowdon, D. A., Greiner, L. H., Mortimer, J. A., et al. (1997) · PubMed · Cited by 846
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 1×
“Treatment with antihypertensives in the HYVET-COG study also showed that pharmacological intervention reduced cardiovascular disease risk of older people, including strokes, but did not reduce not the risk of dementia [11].”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease-Reply
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550020046024 · Cited by 674 · cited 1×
“Lowering cholesterol levels to preserve cognitive function has received much attention with the increasing emphasis on vascular disease as a risk factor of dementia and cognitive impairment [1, 16].”
BackgroundRockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516 · cited 1×
“Cross-sectional and case-control studies have generally indicated a beneficial effect of statins on cognitive outcomes [5, 12 , 18], while observational studies with long follow-up periods have failed to confirm these results [17, 19].”
ResultThe design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Self-citationSimvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Wolozin, B., Wang, S. W., Li, N.-C., Lee, A., Lee, T. A., & Kazis, L. E. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-20 · Cited by 383
Brain Infarction and the Clinical Expression of Alzheimer Disease
Roman, G. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550020045023 · Cited by 350 · cited 1×
“Lowering cholesterol levels to preserve cognitive function has received much attention with the increasing emphasis on vascular disease as a risk factor of dementia and cognitive impairment [1, 16].”
BackgroundZandi, P. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.217 · Cited by 310 · cited 1×
“Cross-sectional and case-control studies have generally indicated a beneficial effect of statins on cognitive outcomes [5, 12, 18], while observational studies with long follow-up periods have failed to confirm these results [17, 19].”
ResultUse of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Cramer, C., Haan, M. N., Galea, S., Langa, K. M., & Kalbfleisch, J. D. (2008) · Neurology · doi:10.1212/01.wnl.0000319647.15752.7b · Cited by 253 · cited 1×
“Cross-sectional and case-control studies have generally indicated a beneficial effect of statins on cognitive outcomes [5, 12, 18], while observational studies with long follow-up periods have failed to confirm these results [17, 19].”
ResultElevated Low-Density Lipoprotein in Alzheimer's Disease Correlates with Brain Aβ 1–42 Levels
Kuo, Y.-M., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C., Drumm, D., & Roher, A. E. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9652 · Cited by 238 · cited 1×
“High total serum cholesterol levels have been shown to associate with lower cerebral spinal fluid levels of b-amyloid and larger amounts of b-amyloid deposition in brain autopsy studies [9, 10].”
BackgroundShapira, I. L. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0118 · Cited by 233
Testing cognitive function in elderly populations: the PROSPER study
Houx, P. J. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.385 · Cited by 151 · cited 1×
“The reliability and sensitivity of these tests in an elderly population have been assessed and presented elsewhere [7].”
BackgroundThe influence of age on the association between cholesterol and cognitive function
van Vliet, P., van de Water, W., de Craen, A. J. M., & Westendorp, R. G. J. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.05.004 · Cited by 86 · cited 3×
“Observational studies have shown that high cholesterol levels in middle age are a risk factor for cognitive impairment later in life [17].”
BackgroundResultSelf-citationSerum Cholesterol and Cerebrospinal Fluid Amyloid β Protein in Alzheimer'S Disease
Okamura, N., Arai, H., Maruyama, M., Matsui, T., Tanji, H., Sasaki, H., Yoshida, H., & Sugita, M. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49293.x · Cited by 7 · cited 1×
“High total serum cholesterol levels have been shown to associate with lower cerebral spinal fluid levels of b-amyloid and larger amounts of b-amyloid deposition in brain autopsy studies [9, 10].”
BackgroundLate-breaking science abstracts
(2008) · Neurology · doi:10.1212/01.wnl.0000325578.26215.c5 · Cited by 7
Late Breaking Science Abstracts
(2004) · Neurology · doi:10.1212/wnl.63.8.1545 · Cited by 4
Alzheimer’s disease: from pathogenesis to novel therapeutic approaches
Scarpini, E. A., & Galimberti, D. (2009) · Therapy · doi:10.2217/14750708.6.2.259 · Cited by 1 · cited 1×
“Two major statin trials are currently under way to assess the effects of statins in delaying the progression of AD in patients with serum cholesterol levels that do not require therapeutic intervention [13].”
Background
Cited by
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Metadata
- Authors
- Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., Stott, D. J., Shepherd, J., Bollen, E. L. E. M., Blauw, G. J., Jukema, J. W., & Westendorp, R. G. J.
- Affiliations
- Leiden University Medical Center (NL)
- Vrije Universiteit Amsterdam (NL)
- Cork University Hospital (IE)
- University of Glasgow (GB)
- Corresponding author
- Trompet, Stella
- ORCID
- Venue
- Journal of Neurology
- Published
- 2009-08-04
- Volume
- 257
- Issue
- 1
- Pages
- 85-90
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2106630714
- Cited by
- 291
- References
- 25
- Citations by year
- 2026: 6 · 2025: 23 · 2024: 18 · 2023: 15 · 2022: 15 · 2021: 15 · 2020: 17 · 2019: 21 · 2018: 18 · 2017: 21 · 2016: 15 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 16
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- green
- research.vu.nl
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb (2001 D 032)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- pravastatin, statins, cognitive decline, dementia prevention, older adults, PROSPER trial, cognitive function, neuropsychological assessment, lipid-lowering therapy
- MeSH terms
- Aged, Aging, Anticholesteremic Agents, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Male, Neuropsychological Tests, Prospective Studies, Time Factors, Treatment Outcome, Pravastatin, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.